九典制藥(300705.SZ):鹽酸左西替利嗪片擬中標第二批全國藥品集中採購
格隆匯1月17日丨九典制藥(300705.SZ)公佈,2020年1月17日,公司已通過國家藥品監督管理局仿製藥質量和療效一致性評價的鹽酸左西替利嗪片參加了全國藥品集中採購並擬中標,擬中標產品基本情況如下:
藥品名稱:鹽酸左西替利嗪片;規格:5mg;包裝數量:24片;適應症:治療下述疾病的過敏相關的症狀:過敏性鼻炎(包括季節性持續過敏性鼻炎和常年性持續性過敏性鼻炎)及慢性特發性蕁麻疹。擬中標價格:1.38元
此次擬中標的品種如確認中標,醫療機構應優先使用此次藥品集中採購中選藥品,並確保完成約定採購量。後續簽訂購銷合同並實施後,將提升公司品牌影響力,對公司長遠發展產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.